Of 34 breast cancer patients with pulmonary nodules and no other evidence for metastatic disease, progression occurred in only 3 (of the 26) whose nodules were < 1 cm in diameter, compared with all 8 in whom the nodules were > 1 cm.
Options for CML blast phase after imatinib failure have been very limited.
In a post hoc analysis of patients entered on a prostate cancer clinical trial, among those receiving androgen suppression therapy, those with higher levels of comorbidity were more likely to suffer adverse consequences, and this was particularly evident for those who had lower risk for prostate cancer specific mortality.
A European multi-institutional trial compared outcome in terms of three-year disease-free and overall survival for patients with colon cancer who had resection either by laparoscopic approach or laparotomy.
In a large series of MGUS patients followed prospectively, transformation to multiple myeloma or other hematological malignancy, although present, was at a rate considerably lower than expected, based upon reports from retrospective series. Nevertheless, overall survival for MGUS patients was significantly less than that for the general population.
